Alligator Bioscience AB Interim Report January-September 2017

REGULATORY

Significant events, July-September
• Aptevo Therapeutics and Alligator Bioscience signed a co-development agreement on the bispecific antibody ALG.APV-527. Preclinical development and initial production activities for clinical trial materials for ALG.APV-527 commenced.

• The immuno-oncology collaboration with Stanford University was expanded. The aim is to predict the clinical efficacy of Alligator’s pipeline candidates using biomarkers.

• A research contract was signed with Professor Ignacio Melero, MD, PhD, from the University of Navarra in Spain, for 4-1BB as a target molecule in immunotherapy and cancer therapy.

• The results of the Alligator-led Phase I clinical trial for ADC-1013/JNJ-64457107 will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November.

• Janssen’s Phase I clinical trial for ADC-1013/JNJ-64457107 is ongoing with approximately 50 patients recruited to date.

Events after the end of the period
Alligator and collaboration partner Aptevo Therapeutics announced on 24 October that the tumor antigen 5T4, associated with many forms of solid tumors, is the second target for ALG.APV-527.

Financial summary
July-September

• Net sales, SEK 1.8 million (4.7).

• Operating loss, SEK 24.5 million (loss: 9.1).

• Loss for the period, SEK 25.8 million (loss: 7.5).

• Loss per share, SEK 0.36 (loss: 0.13).

• Cash and cash equivalents incl. bonds, SEK 588 million (659).

January-September

• Net sales, SEK 5.6 million (51.8).

• Operating loss, SEK 73.0 million (loss: 34.0)

• Loss for the period, SEK 76.3 million (loss: 29.0)

• Loss per share, SEK 1.07 (loss: 0.49)

• Cash flow for the period was a negative SEK 141.5 million (neg: 23.8), of which SEK 74.5 million was invested in corporate bonds.

• During the period, 1,275,000 warrants (230,000) were exercised for an equivalent number of shares.

Financial summary (Group) 2017 2016 2017 2016 2016
Jul-Sep Jul-Sep Jan-Sep Jan-Sep Jan-Dec
Net sales, TSEK 1,770 4,661 5,576 51,808 58,240
Operating profit/loss, TSEK -24,459 -9,133 -73,032 -33,952 -56,082
Profit/loss for the period, TSEK  -25,772 -7,545 -76,274 -29,008 -48,356
Cash flow for the period, TSEK -25,409 -17,780 -141,479 -23,759 287,135
Cash and cash equivalents including bonds, TSEK 587,578 346,457 513,220 346,457 659,136
Equity ratio, % 97% 97% 97% 97% 96%
R&D costs as % of operating costs excluding impairments 69.3% 58.3% 69.5% 62.2% 64.3%
Earnings per share before dilution, SEK -0.36 -0.13 -1.07 -0.49 -0.80
Earnings per share after dilution, SEK -0.36 -0.13 -1.07 -0.49 -0.80
Average number of employees 43 33 40 31 31

The complete report is attached in the link below.

For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com, +46 46 286 42 80.
Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com, +46 46-286 42 85.
Rein Piir, VP IR, rein.piir@alligatorbioscience.com, +46 46 286 42 80.

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46 46-286 42 80. http://www.alligatorbioscience.com

Alligator Bioscience AB (publ) is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact persons set out above, for publication on October 25, 2017 at 08.00 a.m. CEST.

Download as PDF